COMP <GO>
MIRM vs ABBV // EV/EBITDA & P/E VALUATION
Mirum Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MIRM 5
— ABBV 9
■ METRIC PARITY
LAST: $85.00 (-1.61%) • MKT CAP: $5.61B
valuation
—
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MIRM VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MIRM | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | 29.00% | -32.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.98% | 3.47% | -2.49 | ABBV | /fcf-yield <GO> |
| Operating Margin | -4.20% | 24.60% | -28.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -4.50% | 6.90% | -11.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 54.70% | 8.60% | +46.10 | MIRM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.29 | 5.33 | +0.96 | MIRM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | MIRM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | MIRM | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 72.8 | -24.09 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.15 | -0.16 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 113.1x | -81.10 | MIRM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.61B | $513.86B | -$508.25B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MIRM REV | ABBV REV | MIRM GROSS % | ABBV GROSS % | MIRM FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $521.3M | $61.16B | 44.0% | 70.2% | $54.9M | $17.82B |
| FY 2024 | $336.9M | $56.33B | 44.0% | 70.0% | $9.3M | $17.83B |
| FY 2023 | $186.4M | $54.32B | 44.0% | 44.0% | -$79.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MIRM // BETA 0.99
ABBV // BETA 1.15